Program
TSL2109
A development code. Also written as “Treatment arm: TSL2109 capsules。Oral administration。”.
Its studies are mostly in Prostatic Neoplasms, led by China Resources Pharmaceutical Group.
Furthest: phase 1, since Feb 25, 20261 company-led study, 1 open or runningNext primary completion: Dec 31, 2026 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| China Resources Pharmaceutical Group | 11 open or running | phase 1since Feb 25, 2026 | Feb 25, 2026 | Dec 31, 2026phase 1 · NCT07514065 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 25, 2026First study: phase 1 study in Metastatic Castration-Resistant Prostate Cancer PatientsFirst studyNCT07514065 · 78 planned · China
Ahead
- Dec 31, 2026Primary completion: phase 1 study in Metastatic Castration-Resistant Prostate Cancer PatientsNCT07514065
TargetBeta
CDK4 →read by rule
“TSL2109 is a novel CDK4/6-DYRK2 dual-target inhibitor developed by Jiangsu Tasly Diyee Pharmaceutical Co., Ltd.”study text, by rule · the study
Other programs on CDK4
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| abemaciclibrule | Eli Lilly | phase 4 | 49 |
| palbociclibrule | Pfizer | phase 4 | 36 |
| trilaciclibrule | Pharmacosmos | phase 4 | 14 |
| atirmociclib | Pfizer | phase 3 | 17 |
| culmerciclib | Sino Biopharmaceutical | phase 3 | 11 |
| HRS-6209 | Jiangsu HengRui Medicine | phase 3 | 7 |
| CDK4 Inhibitor BGB-43395rule | BeOne Medicines | phase 3 | 4 |
| narazaciclibrule | hangzhou-hanx-biopharmaceuticals-ltd | phase 2 | 4 |
| vustanaciclib | regor-pharmaceuticals-inc | phase 2 | 3 |
| CG-7321rule | chengdu-cynogen-bio-pharmaceutical-tech-co-ltd | phase 1 | 1 |
| nkt5097 cdk2rule | nikang-therapeutics-inc | phase 1 | 1 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07514065Metastatic Castration-Resistant Prostate Cancer Patients · China | 1 | Recruiting | Dec 31, 2026 | 78 |
How it is read
Names in the registry
- “Treatment arm: TSL2109 capsules。Oral administration。”, 1 entry
Codes read as this program: TSL2109.
Conditions, from the studies’ own filings
- Prostatic Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.